Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer

Official record

Identifier

NCT07849608

Recruiting locations

country

China

Interventions studied

AI-Based Digital Pathology Assessment of Treatment Response (DeepTRG)

Lead sponsor

Qun Zhao

Target enrolment

200 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Sep 30, 2026

Last updated on the registry

Sep 30, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age 18 years or older.
* Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II or III), diagnosed before neoadjuvant treatment.
* Received neoadjuvant anticancer treatment before planned surgical resection.
* Scheduled to undergo surgical resection with curative intent at the Fourth Hospital of Hebei Medical University, with routine pathological examination of the primary tumor site and regional lymph nodes.
* Written informed consent obtained in accordance with the ethics-approved study protocol.

Exclusion Criteria:

* Non-adenocarcinoma malignancies, including squamous cell carcinoma, lymphoma, gastrointestinal stromal tumor, or neuroendocrine carcinoma.
* Surgery for recurrent gastric or gastroesophageal junction cancer.
* Previous inclusion of the patient's tissue or data in DeepTRG model training, grading-rule development, or parameter tuning.

Patients will not be excluded because of a complete pathological response, positive surgical margins, poor-quality or unavailable slides, digitization failure, algorithm failure, or uncertain or unassessable DeepTRG results. Technical limitations identified after enrollment will be recorded and retained in the feasibility analysis. Patients who do not proceed to surgical resection will be documented in the study flow and will not contribute to the specimen-based primary outcome denominator.

Indexed under

Gastric Cancer